SAN1L Q1 2010 Analyst Update and Comment, Target Price 04/27/10
- Q1 2010 MAY BE THE BEGINNING OF SUCCESSFUL YEAR;
- YEAR 2009 WAS PROFITABLE DESPITE DROP IN REVENUES;
- LETTER OF INTENT;
- GROWING AND RECOVERING MARKETS MAY INCREASE THE TOTAL SALES IN LONG-TERM;
- BBA INVESTMENT RATING;
10 pages
This report provides analyst comment on company’s latest events and performance. Report contains target price, forecast on business risk (short-, mid-, and long-term) and growth possibilities (long-term) of the company, providing reader with necessary information to make decisions. Key reasons to read this report:
- Report contains only relevant information, leaving out excessive data.
- Understand company’s opportunities, competitive situation and business risk.
- Understand which events influence company performance.
- Understand which events influence the situation of industry.
- Independent analyst comment and opinion.
This report will become available for purchase after you register and log in
Price for this Report: €70 / $100
Price for 30-days Unlimited Report Access (subscription includes all our reports): €30 / $50
Price for 30-days Unlimited Report Access for Enterprises (full access for all users at Your Company):
starting from €350 / $500. For Enterprise Access, please contact us.
Contents:
- SHARE PRICE WILL BE AFFECTED BY POSITIVE FINANCIAL RESULTS; - Q1 2010 MAY BE THE BEGINNING OF SUCCESSFUL YEAR;
- YEAR 2009 WAS PROFITABLE DESPITE DROP IN REVENUES;
- LETTER OF INTENT;
- GROWING AND RECOVERING MARKETS MAY INCREASE THE TOTAL SALES IN LONG-TERM;
- BBA INVESTMENT RATING;
10 pages
This report provides analyst comment on company’s latest events and performance. Report contains target price, forecast on business risk (short-, mid-, and long-term) and growth possibilities (long-term) of the company, providing reader with necessary information to make decisions. Key reasons to read this report:
- Report contains only relevant information, leaving out excessive data.
- Understand company’s opportunities, competitive situation and business risk.
- Understand which events influence company performance.
- Understand which events influence the situation of industry.
- Independent analyst comment and opinion.
This report will become available for purchase after you register and log in
Price for this Report: €70 / $100
Price for 30-days Unlimited Report Access (subscription includes all our reports): €30 / $50
Price for 30-days Unlimited Report Access for Enterprises (full access for all users at Your Company):
starting from €350 / $500. For Enterprise Access, please contact us.
AB Sanitas, together with its subsidiaries, engages in the manufacture, development, and sale of generic medicines. It offers products in various forms, including tablets, capsules, eye drops, ointments, injectables, sterile powders, and semi solids. The company also provides contract manufacturing services, as well as engages in real estate activities. It sells its products primarily in Poland, the Russian Federation, Latvia, Germany, Slovakia, and Lithuania. The company was founded in 1922 and is based in Kaunas, Lithuania.
Latest News
BBA: Q1 2010 May Be The Beginning Of Successful Year For Sanitas AB (SAN1L)
Consolidated profit before tax of Sanitas Group for 3 months of 2010 amounted to 16.9 million LTL
Consolidated profit before tax of Sanitas Group for 3 months of 2010 amounted to 16.9 million LTL
BBA expects net profit margins of Sanitas to increase slightly in mid-term
In Q3 2009, Company’s revenues decreased by 19% compared to Q3 2008.
In Q3 2009, Company’s revenues decreased by 19% compared to Q3 2008.
